- Home
- ASMB vs CEPF Comparison
ASMB vs CEPF Comparison
Compare ASMB & CEPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASMB | CEPF |
|---|---|---|
| Founded | 2005 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.1M | 594.9M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASMB | CEPF |
|---|---|---|
| Price | $26.49 | $10.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $44.20 | N/A |
| AVG Volume (30 Days) | ★ 140.4K | 35.7K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $638.39 | N/A |
| P/E Ratio | ★ N/A | $96.45 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.50 | $10.09 |
| 52 Week High | $39.71 | $10.67 |
Technical Indicators
Market Signals| Indicator | ASMB | CEPF |
|---|---|---|
| Relative Strength Index (RSI) | 45.20 | 46.44 |
| Support Level | $21.80 | $10.37 |
| Resistance Level | $30.36 | $10.48 |
| Average True Range (ATR) | 1.30 | 0.04 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 18.77 | 11.11 |
Price Performance
Historical ComparisonAbout ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
About CEPF Cantor Equity Partners IV Inc. Class A Ordinary Shares
Cantor Equity Partners IV Inc is a blank check company.